Former Bristol Exec Albright Named CSO of Editas

Ben Fidler

Ben Fidler

August 22nd, 2016

Xconomy Boston —

Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.

Ben Fidler is Xconomy's Deputy Editor, Biotechnology. You can e-mail him at bfidler@xconomy.com Follow @benthefidler

Trending on Xconomy

Underwriters and Partners

Xpertise: Watch + Learn

Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed

Sponsored · Whitepaper
Protecting Your Science: Storage & Monitoring for Life Science Organizations
Keep easily accessible, historical records to aid in root cause analysis for deviations
XiltriX

Sponsored · Whitepaper
Protecting Your Life Science Manufacturing Operations: Monitoring Solutions
Implementing a reliable and auditable monitoring program for life science samples, assets & equipment
XiltriX

Tweets from https://twitter.com/Xconomy/lists/lifesci